INGN 225

Explore a selection of our essential drug information below, or:

Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.

SUBSCRIBERECOMMENDED FOR PHARMA

Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Overview

DrugBank ID: DB05325
Type: Biotech
US Approved: NO
Other Approved: NO
Patents: 0
Indicated Conditions: 0
Clinical Trials: Phase 0
0
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0

Identification

Generic Name: INGN 225
DrugBank Accession Number: DB05325
Background: INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53. INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer.
Type: Biotech
Groups: Investigational
Biologic Classification: Protein Based Therapies
Other protein based therapies
Protein Chemical Formula: Not Available
Protein Average Weight: Not Available
Sequences: Not Available
Synonyms: Not Available

Pharmacology

Indication: Investigated for use/treatment in breast cancer, head and neck cancer, and lung cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics: INGN 225 uses the p53 tumor suppressor in a different manner than ADVEXIN to create a molecular immunotherapy for cancer that stimulates a particular type of immune system cell known as a dendritic cell. Testing has shown that the human immune system can recognize and kill tumors after treatment with dendritic cells stimulated by the p53 tumor suppressor, which suggests this therapy could have broad utility as a treatment for solid tumors. INGN 225 may also sensitize tumors to the effects of platinum and taxane chemotherapies.
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Abatacept	The therapeutic efficacy of INGN 225 can be decreased when used in combination with Abatacept.
Adalimumab	The therapeutic efficacy of INGN 225 can be decreased when used in combination with Adalimumab.
Aldesleukin	The therapeutic efficacy of INGN 225 can be decreased when used in combination with Aldesleukin.
Alefacept	The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alefacept.
Alemtuzumab	The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alemtuzumab.

Food Interactions

Not Available

Chemical Identifiers

UNII: Not Available
CAS number: Not Available

References

General References

Not Available

External Links

PubChem Substance: 347910082

Clinical Trials

Clinical Trials Clinical Trial & Rare Diseases Add-on Data Package Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package

Phase	Status	Purpose	Conditions	Count	Start Date	Why Stopped	100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
2	Completed	Treatment	Small Cell Lung Cancer (SCLC)	1	somestatus	stop reason	just information to hide

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State: Solid
Experimental Properties: Not Available

Drug created at November 18, 2007 18:23 / Updated at June 12, 2020 16:52